Endocrine Abstracts

Background: We used Mendelian randomization and machine learning (gradient boosting) to assess the causal association of Type 2 Diabetes with osteoporosis.Methods: We selected 155 SNPs associated with type 2 diabetes and glycaemic and insulin-related traits reported in previous studies (1,2) and studied the association with Heel bone mineral density (BMD)) (n= 4 72 996) and risk of fragility fractures (26 157 cases and 17 807 controls) in UKBiob...

PCOS is the most common endocrine disorder affecting the women of reproductive age group and weight loss is the mainstay of management of PCOS. We performed an open-label randomised controlled trial to compare the effects of a conventional energy deficit approach (-600 kcal/day of the total energy requirements) vs. a very low-calorie diet (VLCD: 800 kcal/day) on free androgen index (FAI), body weight, and metabolic markers in women with PCOS. Forty-one eligible patients were r...

Background: Empagliflozin is a sodium-glucose-cotransporter-2 that improves cardiovascular risk and weight loss in patients with type 2 diabetes. Polycystic ovary syndrome (PCOS) is associated with obesity and increased cardiovascular risk; therefore, empagliflozin may be of benefit in PCOS.Methods: A randomised, open-label study in 40 overweight and obese women with PCOS treated with either empagliflozin 25 mg or metformin 1500mg daily for 12 weeks....